anti-CDK4/6
-
January 17, 2017
In Metastatic Breast Cancer Treatment, Not All CDK Inhibitors Are Equal
Emma Shtivelman, PhDDoctors prescribe drugs known as CDK inhibitors to treat some women with estrogen-receptor-positive (ER+) metastatic breast cancer. Research into these drugs is ongoing, and new, promising CDK inhibitor options are on the horizon. Here, I address the current outlook for CDK inhibitors in ER+ breast cancer. First, some background: ER+ breast cancers comprise about 70% of all breast cancers. The name reflects the fact… Read more »